Shots:
The CHMP has recommended Pebrilzo, a biosimilar version of Perjeta (pertuzumab), as the 420 mg concentrate solution for infusion for the treatment of HER2+ breast cancer across multiple disease stages
The EC will conduct the final review and issue its decision; if positive, the SmPC will be available in all EU official languages, with…
